Incidence of CNS irAEs like meningitis and encephalitis is significantly higher in melanoma patients with history of anti-PD-1/CTLA-4 combination therapy than in those treated with anti-PD-1 monotherapy. This evidence concerns the gene CTLA4 and meningitis.